Want to see IL:BLRX full AI Analyst Report?
Bioline Rx (BLRX) Financial Statements
Bioline Rx Financial Overview
Bioline Rx's market cap is currently $29.87M. The company's EPS TTM is $-0.00; its P/E ratio is -1.03; Bioline Rx is estimated to report earnings on November 18, 2026, and the estimated EPS forecast is $-0.31. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.28M | $ 28.94M | $ 4.80M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 462.21K | $ 19.68M | $ 1.11M | $ 0.00 | $ 0.00 |
| Operating Income | $ -11.14M | $ -20.41M | $ -49.69M | $ -29.16M | $ -24.78M |
| EBITDA | $ -10.61M | $ 3.92M | $ -57.09M | $ -28.50M | $ -24.07M |
| Net Income | $ -1.27M | $ -9.22M | $ -60.61M | $ -20.75M | $ -28.14M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 20.88M | $ 19.56M | $ 42.99M | $ 51.08M | $ 57.13M |
| Total Assets | $ 40.91M | $ 38.91M | $ 63.92M | $ 76.38M | $ 81.39M |
| Total Debt | $ 10.15M | $ 15.04M | $ 11.59M | $ 12.32M | $ 4.65M |
| Net Debt | $ 6.90M | $ 4.60M | $ 7.34M | $ 1.74M | $ -8.34M |
| Total Liabilities | $ 17.56M | $ 25.45M | $ 50.70M | $ 25.54M | $ 13.30M |
| Stockholders' Equity | $ 18.20M | $ 13.46M | $ 13.22M | $ 50.84M | $ 68.09M |
| Cash Flow | |||||
| Free Cash Flow | $ -8.77M | $ -43.93M | $ -22.91M | $ -26.56M | $ -23.67M |
| Operating Cash Flow | $ -8.74M | $ -43.87M | $ -22.61M | $ -26.24M | $ -23.57M |
| Investing Cash Flow | $ -9.25M | $ 29.37M | $ 1.44M | $ 4.01M | $ -38.22M |
| Financing Cash Flow | $ 9.62M | $ 20.66M | $ 15.06M | $ 20.44M | $ 57.75M |
Currency in USD